Cancer BiologybioRxivPreprint
Discoidin domain receptor 2 drives melanoma drug resistance through AXL-dependent phenotype switching
M. Sala, N. Allain, A. Jabouille…·F. Saltel
This study shows DDR2 drives melanoma drug resistance via AXL-dependent phenotype switching, suggesting DDR inhibition as a potential second-line treatment.
DOI 10.1101/857904